Influenza vaccination to improve outcomes for patients with acute heart failure (PANDA II): a multiregional, seasonal, hospital-based, cluster-randomised, controlled trial in China.

Background: Influenza vaccination is widely recommended to prevent death and serious illness in vulnerable people, including those with heart failure. However, the randomised evidence to support this practice is limited and few people are vaccinated in many parts of the world. We aimed to determine whether influenza vaccination can improve the outcome of patients after an episode of acute heart failure requiring admission to hospital in China.

Risk factors and mitigation strategies of laboratory-acquired infections in research and clinical laboratories worldwide: a systematic review.

Laboratory-acquired infections and accidental pathogen escapes from laboratory settings pose biosafety risks, affecting laboratory personnel, the scientific community, the general public, animal populations, and the environment. This systematic review compares reports of laboratory-acquired infections and accidental pathogen escapes from laboratory settings in research and clinical laboratories between 2000 and 2024, identifying key risk factors. A total of 250 reports documenting 712 human cases of laboratory-acquired infections were analysed.

Tracing the spatial origins and spread of SARS-CoV-2 Omicron lineages in South Africa.

Since November 2021, five genetically distinct SARS-CoV-2 Omicron lineages (BA.1-BA.5) are believed to have emerged in southern Africa, with four (BA.